Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kissei Pharmaceutical Co ( (JP:4547) ) has provided an update.
Kissei Pharmaceutical reported record-high consolidated revenue for the fiscal year ended March 31, 2026, with net sales rising 10.3% year on year to ¥97.4 billion, driven by 3.5% growth in its pharmaceutical business and a 49.3% surge in other businesses. Strong performance came from domestic sales of Beova, TAVNEOS, KORSUVA, and TAVALISSE, as well as expanding overseas markets for Linzagolix and Fostamatinib.
Despite higher selling, general and administrative costs, mainly from R&D and in-licensing fees for two thyroid eye disease drugs and new clinical trials, the company turned extraordinary gains on sales of investment securities into a 15.2% increase in net income attributable to owners of the parent. Its information services arm also delivered significant growth by winning projects related to the GIGA School policy, underscoring a diversified earnings base even as core pharmaceutical investment pressures operating profit.
The most recent analyst rating on (JP:4547) stock is a Buy with a Yen5400.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Section, focusing on prescription drugs and related healthcare businesses. Its operations span domestic pharmaceuticals, overseas licensing of products such as Linzagolix and Fostamatinib, and other businesses including information services tied to education-sector digital initiatives.
Average Trading Volume: 89,982
Technical Sentiment Signal: Buy
Current Market Cap: Yen178.5B
For an in-depth examination of 4547 stock, go to TipRanks’ Overview page.